CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate

combination drug

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 5, 2026
Entity authorityQ64363017 ↗
Source-derived summary

Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate (EB/EPP/TP/TPP/TiC), sold under the brand names Estandron Prolongatum, Lynandron Prolongatum, and Mixogen, was an injectable combination medication of the estrogens estradiol benzoate (EB) and estradiol phenylpropionate (EPP) and the androgens/anabolic steroids testosterone propionate (TP), testosterone phenylpropionate (TPP), and testosterone isocaproate (TiC) which was used in menopausal hormone therapy for women. It was also used to suppress lactation in postpartum women.

The medication was provided in the form of 1 mL ampoules and 2 mL vials containing 1 mg/mL EB, 4 mg/mL EPP, 20 mg/mL TP, 40 mg/mL TPP, and 40 mg/mL TiC in an oil solution and was administered by intramuscular injection. EB/EPP/TP/TPP/TiC reportedly has a duration of about 14 days.

Estandron Prolongatum, Lynandron Prolongatum, and Mixogen were all introduced for medical use by 1956. Oral tablet products with the same brand names of Estandron, Lynandron, and Mixogen, containing ethinylestradiol and methyltestosterone, were marketed around the same time, and should not be confused with the injectable products. Estandron Prolongatum, Lynandron Prolongatum, and Mixogen remained marketed as late as the 1980s. EB/EPP/TP/TPP/TiC appears to no longer be marketed.

Editorial summary

This brief starts where responsible research should: with the source description of “Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate” as combination drug. Everything that follows is an evidence route, not borrowed authority.

Editorial reviewA concise reference frame for defining the subject, testing terminology and identifying the institution closest to the evidence. The current lead gives the account dated anchors—1956—that can be checked directly. The selected authority fields contribute no independent date. The account is most persuasive where Estradiol, benzoate and estradiol can be independently traced.
Editorial analysis

Why this record matters

The subject matters to the general reference register because the source frames it as combination drug. Its deeper value depends on whether names, dates, institutions and citations support that framing.

Evidence profile

The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Aug 5, 2026. The linked authority identifier is Q64363017. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1956.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate”, its source revision and the description used here.
  2. Expand the search: follow Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate primary sources, Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate archive and Estradiol research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate”?
  2. Which cited source is closest to the event, object or claim?
  3. What terminology or title could unlock a more precise catalogue search?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Estradiol benzoate/estradiol phenylpropionate/testosterone propionate/testosterone phenylpropionate/testosterone isocaproate” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.